| Pair Name | Oridonin, Imatinib | ||
| Phytochemical Name | Oridonin (PubChem CID: 5321010 ) | ||
| Anticancer drug Name | Imatinib (PubChem CID: 123596 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Oridonin, Imatinib | |||
| Disease Info | [ICD-11: 2B33.3] | Acute lymphoblastic leukemia | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | AKT1 | hsa207 |
| Up-regulation | Expression | BAX | hsa581 | |
| Up-regulation | Expression | BCL2 | hsa596 | |
| Down-regulation | Expression | JTK8 | hsa4067 | |
| Down-regulation | Expression | MEK1 | hsa5604 | |
| Down-regulation | Expression | MTOR | hsa2475 | |
| Down-regulation | Expression | RAF1 | hsa5894 | |
| Down-regulation | Expression | STAT5B | hsa6777 | |
| In Vitro Model | SUP-B15 | Childhood B acute lymphoblastic leukemia with t | Homo sapiens (Human) | CVCL_0103 |
| Result | Our data showed that oridonin remarkably suppressed activations of Akt/mTOR, Raf/MEK and STAT5 pathway in these primary specimens and oridonin with imatinib exerted synergetic suppressive effects on mTOR, STAT5 and LYN signaling in one imatinib resistant patient specimen. Additional evaluation of oridonin as a potential therapeutic agent for Ph+ ALL seems warranted. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. Cancer Biol Ther. 2012 Nov;13(13):1244-54. doi: 10.4161/cbt.21460. | Click |
